Prescription pharmaceuticals market

Global Prescription Pharmaceuticals Market, By Therapeutic Segment (Cardiovascular Disorders, Inflammatory Conditions, Metabolic Disorders, Oncology, Respiratory Disorders, Others), By Formulations (Capsules, Inhalants, Parenterals, Tablets, Topicals), By Region (Asia, Europe, North America and Rest of the World (RoW) – Market Size and Forecast (2013–2020) Scalar Market Research.

June 2016

1

Table of Contents Market Overview ..................................................................................................................................16

1

1.1

Definitions.............................................................................................................................16

1.2

Research Methodology .........................................................................................................16

1.3

Market Segmentation ...........................................................................................................17

Executive Summary.......................................................................................................................19 1.1

Global Prescription Pharmaceuticals Market .......................................................................19

1.2 Global Prescription Pharmaceuticals Market Size (US$ Billion), By Therapeutic Segments (2015 vs. 2020)..................................................................................................................................20 1.3 Global Prescription Pharmaceuticals Market Size (US$ Billion), By Formulations (2015 vs.

2020) 21

2.1

PL

Market Overview ..........................................................................................................................23 Drivers ...................................................................................................................................23 Increase in the Ageing Population and Lengthening Life Expectancies........................23

2.1.2

Rising Affluence in Emerging Markets ..........................................................................23

2.1.3

Widespread Prevalence of Chronic Diseases................................................................23

2.2

M

2.1.1

Restraints ..............................................................................................................................24

SA

2

Global Prescription Pharmaceuticals Market Size (US$ Billion), By Regions (2015 vs. 2020) 21

E

1.4

2.2.1

Government Policies Aimed at Lowering Prescription Drug Prices ..............................24

2.2.2

Generics and Biosimilars Drugs Hampering Prescription Pharmaceuticals Growth.....24

2.3

Opportunities........................................................................................................................25

2.3.1

Emerging Markets are key Pockets...............................................................................25

2.3.2

Increased Healthcare Awareness..................................................................................25

2.4

Trends ...................................................................................................................................25

2.4.1 Increased Spending on Specialty Medicines – Hepatitis, Autoimmune Diseases, and Oncology 25 3

Industry Analysis ...........................................................................................................................26 3.1

Supply Chain Analysis............................................................................................................26

3.2

Regulatory Analysis ...............................................................................................................29

3.3

Macroeconomic Indicators ...................................................................................................30 2

3.3.1

Healthcare Spending (US$ Billion), by Regions (2005 to 2014) ....................................30

3.3.2

Per Capita Healthcare Spending (US$), by Regions (2005 to 2014)..............................30

3.3.3

Public Healthcare Spending (US$ Billion), by Regions (2005 to 2014)..........................30

3.4

3.4.1

Market Size of Top-25 Prescription Pharmaceuticals (2013 to 2015) ..........................31

3.4.2

Therapeutic Segments Benchmarking ..........................................................................32

Prescription Pharmaceuticals Markets, by Therapeutic Segments ..............................................34 4.1

Introduction ..........................................................................................................................34

4.1.1 Global Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By Therapeutic Segments (2015).......................................................................................................34 4.1.2 Global Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By Therapeutic Segments (2013 – 2020) ...........................................................................................34 Cardiovascular Disorders ......................................................................................................35

E

4.2

PL

4.2.1 Global Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By Cardiovascular Disorders, (2013 – 2020) ......................................................................................36 4.2.2 Global Prescription Pharmaceuticals for Cardiovascular Disorders Market Size & Forecast (US$ billion), By Regions (2015 vs. 2020) .......................................................................36

M

4.2.3 Global Prescription Pharmaceuticals for Cardiovascular Disorders Market Size & Forecast (US$ billion), By Regions (2013 – 2020) .........................................................................37 4.2.4 North America Prescription Pharmaceuticals for Cardiovascular Disorders Market Size & Forecast (US$ billion), By Country (2013 – 2020) .....................................................................37

SA

4

Ecosystem Analysis ...............................................................................................................31

4.2.5 Europe Prescription Pharmaceuticals for Cardiovascular Disorders Market Size & Forecast (US$ billion), By Country (2013 – 2020) .........................................................................38 4.2.6 Asia Prescription Pharmaceuticals for Cardiovascular Disorders Market Size (US$ Billion) & Forecast (US$ billion), By Country (2013 – 2020) .........................................................38 4.2.7 Rest of the World (RoW) Prescription Pharmaceuticals for Cardiovascular Disorders Market Size & Forecast (US$ billion), By Country (2013 – 2020)..................................................38 4.3

Oncology ...............................................................................................................................39

4.3.1 Global Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By Oncology (2013 – 2020) ................................................................................................................................39 4.3.2 Global Prescription Pharmaceuticals for Oncology Market Size & Forecast (US$ billion), By Regions (2015 vs. 2020) ..............................................................................................40 4.3.3 Global Prescription Pharmaceuticals for Oncology Market Size & Forecast (US$ billion), By Regions (2013 – 2020).................................................................................................40 4.3.4 North America Prescription Pharmaceuticals for Oncology Market Size & Forecast (US$ billion), By Country (2013 – 2020)........................................................................................41 3

4.3.5 Europe Prescription Pharmaceuticals for Oncology Market Size & Forecast (US$ billion), By Country (2013 – 2020) ................................................................................................41 4.3.6 Asia Prescription Pharmaceuticals for Oncology Market Size & Forecast (US$ billion),

By Country (2013 – 2020) .............................................................................................................42 4.3.7 Rest of the World (RoW) Prescription Pharmaceuticals for Oncology Market Size & Forecast (US$ billion), By Country (2013 – 2020) .........................................................................42 4.4

Inflammatory Conditions ......................................................................................................42

4.4.1 Global Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By Inflammatory Conditions (2013 – 2020) .......................................................................................43 4.4.2 Global Prescription Pharmaceuticals Market Size & Forecast for Inflammatory Conditions (US$ billion), By Regions (2015 vs. 2020) ...................................................................43 4.4.3 Global Prescription Pharmaceuticals Market Size & Forecast for Inflammatory Conditions (US$ billion), By Regions (2013 – 2020)......................................................................44

E

4.4.4 North America Prescription Pharmaceuticals Market Size & Forecast for Inflammatory Conditions (US$ billion), By Country (2013 – 2020)......................................................................44

PL

4.4.5 Europe Prescription Pharmaceuticals Market Size & Forecast for Inflammatory Conditions (US$ billion), By Country (2013 – 2020)......................................................................45 4.4.6 Asia Prescription Pharmaceuticals Market Size & Forecast for Inflammatory Conditions (US$ billion), By Country (2013 – 2020)......................................................................45

Infectious Diseases................................................................................................................46

SA

4.5

M

4.4.7 Rest of the World (RoW) Prescription Pharmaceuticals Market Size & Forecast for Inflammatory Conditions (US$ billion), By Country (2013 – 2020)...............................................45

4.5.1 Global Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By Infectious Diseases (2013 – 2020) ................................................................................................46 4.5.2 Global Prescription Pharmaceuticals Market Size & Forecast for Infectious Diseases (US$ billion), By Regions (2015 vs. 2020)......................................................................................47 4.5.3 Global Prescription Pharmaceuticals Market Size & Forecast for Infectious Diseases (US$ billion), By Regions (2013 – 2020) ........................................................................................47 4.5.4 North America Prescription Pharmaceuticals Market Size & Forecast for Infectious Diseases (US$ billion), By Country (2013 – 2020) .........................................................................48 4.5.5 Europe Prescription Pharmaceuticals Market Size & Forecast for Infectious Diseases (US$ billion), By Country (2013 – 2020)........................................................................................48 4.5.6 Asia Prescription Pharmaceuticals Market Size & Forecast for Infectious Diseases (US$ billion), By Country (2013 – 2020) ................................................................................................48 4.5.7 Rest of the World (RoW) Prescription Pharmaceuticals Market Size & Forecast for Infectious Diseases (US$ billion), By Country (2013 – 2020) ........................................................49 4.6

Metabolic Disorders..............................................................................................................49 4

4.6.1 Global Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By Metabolic Disorders (2013 – 2020)...............................................................................................49 4.6.2 Global Prescription Pharmaceuticals Market Size & Forecast for Metabolic Disorders (US$ billion), By Regions (2015 vs. 2020)......................................................................................50 4.6.3 Global Prescription Pharmaceuticals Market Size & Forecast for Metabolic Disorders (US$ billion), By Regions (2013 – 2020) ........................................................................................50 4.6.4 North America Prescription Pharmaceuticals Market Size & Forecast for Metabolic Disorders (US$ billion), By Country (2013 – 2020) .......................................................................51 4.6.5 Europe Prescription Pharmaceuticals Market Size & Forecast for Metabolic Disorders (US$ billion), By Country (2013 – 2020)........................................................................................51 4.6.6 Asia Prescription Pharmaceuticals Market Size & Forecast for Metabolic Disorders (US$ billion), By Country (2013 – 2020)........................................................................................51 4.6.7 Rest of the World (RoW) Prescription Pharmaceuticals Market Size & Forecast for Metabolic Disorders (US$ billion), By Country (2013 – 2020) ......................................................52 Respiratory Disorders ...........................................................................................................52

E

4.7

PL

4.7.1 Global Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By Respiratory Disorders (2013 – 2020) ............................................................................................52 4.7.2 Global Prescription Pharmaceuticals Market Size & Forecast for Respiratory Disorders (US$ billion), By Regions (2015 vs. 2020)......................................................................................53

M

4.7.3 Global Prescription Pharmaceuticals Market Size & Forecast for Respiratory Disorders (US$ billion), By Regions (2013 – 2020) ........................................................................................53

SA

4.7.4 North America Prescription Pharmaceuticals Market Size & Forecast for Respiratory Disorders (US$ billion), By Country (2013 – 2020) .......................................................................54 4.7.5 Europe Prescription Pharmaceuticals Market Size & Forecast for Respiratory Disorders (US$ billion), By Country (2013 – 2020)........................................................................................54 4.7.6 Asia Prescription Pharmaceuticals Market Size & Forecast for Respiratory Disorders (US$ billion), By Country (2013 – 2020)........................................................................................55 4.7.7 Rest of the World (RoW) Prescription Pharmaceuticals Market Size & Forecast for Respiratory Disorders (US$ billion), By Country (2013 – 2020) ....................................................55 4.8

Other Therapeutic Segments ................................................................................................55

4.8.1 Global Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By Other Therapeutic Segments (2013 – 2020) ...........................................................................................56 4.8.2 Global Prescription Pharmaceuticals Market Size & Forecast for Other Therapeutic Segments (US$ billion), By Regions (2015 vs. 2020) .....................................................................56 4.8.3 Global Prescription Pharmaceuticals Market Size & Forecast for Other Therapeutic Segments (US$ billion), By Regions (2013 – 2020) .......................................................................57

5

4.8.4 North America Prescription Pharmaceuticals Market Size & Forecast for Other Therapeutic Segments (US$ billion), By Country (2013 – 2020)...................................................57 4.8.5 Europe Prescription Pharmaceuticals Market Size & Forecast for Other Therapeutic Segments (US$ billion), By Country (2013 – 2020) .......................................................................57 4.8.6 Asia Prescription Pharmaceuticals Market Size & Forecast for Other Therapeutic Segments (US$ billion), By Country (2013 – 2020) .......................................................................58 4.8.7 Rest of the World (RoW) Prescription Pharmaceuticals Market Size & Forecast for Other Therapeutic Segments (US$ billion), By Country (2013 – 2020) ........................................58 Prescription Pharmaceuticals Markets, by Formulations .............................................................59 5.1

Introduction ..........................................................................................................................59

5.1.1 Global Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By Formulations (2015)......................................................................................................................59

5.2

E

5.1.2 Global Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By Formulations (2013 – 2020)..........................................................................................................59 Capsules ................................................................................................................................60 Global Capsules Market Size & Forecast (US$ billion) (2013 – 2020)...........................60

5.2.2

Global Capsules Market Size & Forecast (US$ billion), By Regions (2015 vs. 2020) .....61

5.2.3

Global Capsules Market Size & Forecast (US$ billion), By Regions (2013 – 2020) .......61

Tablets...................................................................................................................................62

M

5.3

PL

5.2.1

5.3.1

Global Tablets Market Size & Forecast (US$ billion), (2013 – 2020) ............................62

5.3.2

Global Tablets Market Size & Forecast (US$ billion), By Regions (2015 vs. 2020) .......62

5.3.3

Global Tablets Market Size & Forecast (US$ billion), By Regions (2013 – 2020)..........63

5.4

SA

5

Inhalants and Liquids ............................................................................................................63

5.4.1

Global Inhalants and Liquids Market Size & Forecast (US$ billion), (2013 – 2020)......64

5.4.2 2020)

Global Inhalants and Liquids Market Size & Forecast (US$ billion), By Regions (2015 vs.

64

5.4.3 2020)

Global Inhalants and Liquids Market Size & Forecast (US$ billion), By Regions (2013 – 65

5.5

Parenterals............................................................................................................................65

5.5.1

Global Parenteral Market Size Market Size & Forecast (US$ billion), (2013 – 2020) ...65

5.5.2

Global Parenteral Market Size & Forecast (US$ billion), By Regions (2015 vs. 2020) ..66

5.5.3

Global Parenterals Market Size & Forecast (US$ billion), By Regions (2013 – 2020) ...66

5.6

Topicals .................................................................................................................................67

5.6.1

Global Topicals Market Size & Forecast (US$ billion), (2013 – 2020) ...........................67 6

Global Topicals Market Size & Forecast (US$ billion), By Regions (2015 vs. 2020) ......67

5.6.3

Global Topicals Market Size & Forecast (US$ billion), By Regions (2013 – 2020) ........68

Geographic Analysis ......................................................................................................................69 6.1

Introduction ..........................................................................................................................69

6.1.1

Global Prescription Pharmaceuticals Market Size vs. CAGR% (2015 – 2020), By Regions .......................................................................................................................................69

6.1.2 Global Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By Regions (2013 – 2020) ................................................................................................................................69 6.2

North America.......................................................................................................................70

6.2.1 North America Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By Country (2013 – 2020) ..................................................................................................................70 6.2.2 North America Prescription Pharmaceuticals Market Size & Forecast (US$ billion), (2013 – 2020) ................................................................................................................................70

E

6.2.3 North America Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By Therapeutic Segments (2013 – 2020) ...........................................................................................71

6.3

PL

6.2.4 North America Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By Formulations (2013 – 2020)..........................................................................................................72 Europe...................................................................................................................................73

6.3.2 2020)

M

6.3.1 Europe Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By Country (2013 – 2020) ................................................................................................................................73 Europe Prescription Pharmaceuticals Market Size & Forecast (US$ billion), (2013 – .......................................................................................................................................73

SA

6

5.6.2

6.3.3 Europe Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By Therapeutic Segments (2013 – 2020) ...........................................................................................74 6.3.4 Europe Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By Formulations (2013 – 2020)..........................................................................................................74 6.4

Asia........................................................................................................................................75

6.4.1 Asia Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By Country (2013 – 2020) ................................................................................................................................75 6.5

Asia Prescription Pharmaceuticals Market Size & Forecast (US$ billion), (2013 – 2020).....75

6.5.1 Asia Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By Therapeutic Segments (2013 – 2020) ...........................................................................................76 6.5.2 Asia Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By Formulations (2013 – 2020)..........................................................................................................76 6.6

Rest of the World (RoW).......................................................................................................77 7

6.6.1 RoW Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By Country, (2013 – 2020) ................................................................................................................................77 6.6.2

Row Prescription Pharmaceuticals Market Size & Forecast (US$ billion), (2013 – 2020) .......................................................................................................................................77

6.6.3 RoW Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By Therapeutic Segments (2013 – 2020) ...........................................................................................78 6.6.4 RoW Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By Formulations (2013 – 2020)..........................................................................................................78

7.1

Market Share Analysis...........................................................................................................80

7.2

Market Positioning of Key Players ........................................................................................80

Company Profiles ..........................................................................................................................81 8.1

AstraZeneca (U.K.) ................................................................................................................81 Financial Overview: AstraZeneca plc (U.K.) (Europe) (2013 to 2015)...........................81

8.1.2 2015)

Revenues of Top-3 Pharmaceutical Products AstraZeneca plc (U.K.) (Europe) (2013 to 82

PL

8.2

E

8.1.1

Bayer AG (Germany) .............................................................................................................82

8.2.1

Financial Overview: Bayer AG (Germany) (Europe) (2013 to 2015) .............................83

8.2.2 2015)

Revenues of Top-3 Pharmaceutical Products: Bayer AG (Germany) (Europe) (2013 to .......................................................................................................................................83

8.3

M

8

Competitive Landscape.................................................................................................................80

Gilead Sciences (U.S.)............................................................................................................84

SA

7

8.3.1

Financial Overview: Gilead Sciences, Inc. (U.S.) (2013 to 2015) ...................................84

8.3.2 2015)

Revenues of Top-3 Pharmaceutical Products: Gilead Sciences, Inc. (U.S.) (2013 to .......................................................................................................................................85

8.4

GlaxoSmithKline (U.K.) ..........................................................................................................85

8.4.1

Financial Overview: GlaxoSmithKline plc (U.K.) (Europe) (2013 to 2015) ....................85

8.4.2 Revenues of Top-3 Pharmaceutical Products: GlaxoSmithKline plc (U.K.) (Europe) (2013 to 2015)...............................................................................................................................86 8.5

Johnson & Johnson (U.S.)......................................................................................................87

8.5.1

Financial Overview: Johnson & Johnson (U.S.) (2013 to 2015) ....................................87

8.5.2

Revenues of Top-3 Pharmaceutical Products: Johnson & Johnson (U.S.) (2013 to 2015) .......................................................................................................................................88

8.6

Merck & Co (U.S)...................................................................................................................88

8.6.1

Financial Overview: Merck & Co., Inc. (U.S.) (2013 to 2015)........................................88 8

8.6.2 8.7

Revenues of Top-3 Pharmaceutical Products: Merck & Co., Inc. (U.S.) (2013 to 2015)89

Novartis A.G. (Switzerland) ...................................................................................................90

8.7.1

Financial Overview: Novartis AG (Switzerland) (Europe) (2013 to 2015).....................90

8.7.2 Revenues of Top-3 Pharmaceutical Products: Novartis AG (Switzerland) (Europe) (2013 to 2015)...............................................................................................................................91 8.8

Pfizer (U.S.)............................................................................................................................91

8.8.1

Financial Overview: Pfizer Inc. (U.S.) (2013 to 2015)....................................................91

8.8.2

Revenues of Top-3 Pharmaceutical Products: Pfizer Inc. (U.S.) (2013 to 2015) ...........92

8.9

F. Hoffmann-La Roche (Switzerland) ....................................................................................93

8.9.1

Financial Overview: F. Hoffmann-La Roche (Switzerland) (Europe) (2013 to 2015) ....93

8.9.2 Revenues of Top-3 Pharmaceutical Products: Hoffmann-La Roche (Switzerland) (Europe) (2013 to 2015)................................................................................................................94

8.10.1

Financial Overview: Sanofi S.A. (France) (Europe) (2013 to 2015) ...............................94

8.10.2 2015)

Revenues of Top-3 Pharmaceutical Products: Sanofi S.A. (France) (Europe) (2013 to .......................................................................................................................................95

PL

9

Sanofi S.A.(France) ................................................................................................................94

E

8.10

SCALAR 360 DEGREE MARKET REVIEW.........................................................................................96

M

10 Appendix .......................................................................................................................................96 Acronyms ..............................................................................................................................96

10.2

Contact Us................................................................................ Error! Bookmark not defined.

10.3

Disclaimer................................................................................. Error! Bookmark not defined.

SA

10.1

9

Table 1.

Global Prescription Pharmaceuticals Market ...................................................................19

Table 2.

Global Prescription Pharmaceuticals Market Size (US$ Billion), By Therapeutic Segments (2015 vs. 2020)......................................................................................................................................20 Table 3...................................................................................................................................................20 Global Prescription Pharmaceuticals Market Size (US$ Billion), By Formulations (2015 vs.

21

Table 5.

2020)

Global Prescription Pharmaceuticals Market Size (US$ Billion), By Regions (2015 vs.

21

Table 6.

Healthcare Spending (US$ Billion), by Regions (2005 to 2014) ........................................30

Table 7.

Per Capita Healthcare Spending (US$), by Regions (2005 to 2014)..................................30

Table 8.

Public Healthcare Spending (US$ Billion), by Regions (2005 to 2014)..............................30

Table 9.

Market Size of Top-25 Prescription Pharmaceuticals (2013 to 2015) ..............................31

Table 10.

Therapeutic Segments Benchmarking ..............................................................................32

E

Table 4.

2020)

PL

Table 11. Global Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By Therapeutic Segments (2013 – 2020) .......................................................................................................................34 Table 12. Global Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By Cardiovascular Disorders, (2013 – 2020) ..............................................................................................36

M

Table 13. Global Prescription Pharmaceuticals for Cardiovascular Disorders Market Size & Forecast (US$ billion), By Regions (2013 – 2020) ................................................................................................37

SA

Table 14. North America Prescription Pharmaceuticals for Cardiovascular Disorders Market Size & Forecast (US$ billion), By Country (2013 – 2020) .................................................................................37 Table 15. Europe Prescription Pharmaceuticals for Cardiovascular Disorders Market Size & Forecast (US$ billion), By Country (2013 – 2020) .................................................................................38 Table 16. Asia Prescription Pharmaceuticals for Cardiovascular Disorders Market Size (US$ Billion) for Asia, By Country (2013 – 2020) .......................................................................................................38 Table 17. Rest of the World (RoW) Prescription Pharmaceuticals for Cardiovascular Disorders Market Size & Forecast (US$ billion), By Country (2013 – 2020) .........................................................38 Table 18. Global Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By Oncology (2013 – 2020) ........................................................................................................................................39 Table 19. Global Prescription Pharmaceuticals for Oncology Market Size & Forecast (US$ billion),

By Regions (2013 – 2020)......................................................................................................................40 Table 20. North America Prescription Pharmaceuticals for Oncology Market Size & Forecast (US$ billion), By Country (2013 – 2020) ........................................................................................................41 Table 21. Europe Prescription Pharmaceuticals for Oncology Market Size & Forecast (US$ billion),

By Country (2013 – 2020) .....................................................................................................................41

10

Table 22. Asia Prescription Pharmaceuticals for Oncology Market Size & Forecast (US$ billion), By Country (2013 – 2020) ..........................................................................................................................42 Table 23. Rest of the World (RoW), Prescription Pharmaceuticals for Oncology Market Size & Forecast (US$ billion),By Country (2013 – 2020) ..................................................................................42 Table 24. Global Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By Inflammatory Conditions (2013 – 2020)...............................................................................................43 Table 25. Global Prescription Pharmaceuticals Market Size & Forecast for Inflammatory Conditions (US$ billion), By Regions (2013 – 2020) ................................................................................................44 Table 26. North America Prescription Pharmaceuticals Market Size & Forecast for Inflammatory Conditions (US$ billion), By Country (2013 – 2020)..............................................................................44 Table 27. Europe Prescription Pharmaceuticals Market Size & Forecast for Inflammatory Conditions (US$ billion), By Country (2013 – 2020)..............................................................................45 Table 28. Asia Prescription Pharmaceuticals Market Size & Forecast for Inflammatory Conditions (US$ billion), By Country (2013 – 2020)................................................................................................45

E

Table 29. Rest of the World (RoW) Prescription Pharmaceuticals Market Size & Forecast for Inflammatory Conditions (US$ billion), By Country (2013 – 2020).......................................................45

PL

Table 30. Global Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By Infectious Diseases (2013 – 2020) .........................................................................................................................46

M

Table 31. Global Prescription Pharmaceuticals Market Size & Forecast for Infectious Diseases (US$ billion), By Regions (2015 vs. 2020) ......................................................................................................47

SA

Table 32. Global Prescription Pharmaceuticals Market Size & Forecast for Infectious Diseases (US$ billion), By Regions (2013 – 2020).........................................................................................................47 Table 33. North America Prescription Pharmaceuticals Market Size & Forecast for Infectious Diseases (US$ billion), By Country (2013 – 2020) .................................................................................48 Table 34. Europe Prescription Pharmaceuticals Market Size & Forecast for Infectious Diseases (US$ billion), By Country (2013 – 2020)................................................................................................48 Table 35. Asia Prescription Pharmaceuticals Market Size & Forecast for Infectious Diseases (US$ billion), By Country (2013 – 2020) ........................................................................................................48 Table 36. Rest of the World (RoW) Prescription Pharmaceuticals Market Size & Forecast for Infectious Diseases (US$ billion), By Country (2013 – 2020) ................................................................49 Table 37. Global Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By Metabolic Disorders (2013 – 2020)........................................................................................................................49 Table 38. Global Prescription Pharmaceuticals Market Size & Forecast for Metabolic Disorders (US$ billion), By Regions (2013 – 2020) ................................................................................................50 Table 39. North America Prescription Pharmaceuticals Market Size & Forecast for Metabolic Disorders (US$ billion), By Country (2013 – 2020) ...............................................................................51 Table 40. Europe Prescription Pharmaceuticals Market Size & Forecast for Metabolic Disorders (US$ billion), By Country (2013 – 2020)................................................................................................51 11

Table 41. Asia Prescription Pharmaceuticals Market Size & Forecast for Metabolic Disorders (US$ billion), By Country (2013 – 2020) ........................................................................................................51 Table 42. Rest of the World (RoW) Prescription Pharmaceuticals Market Size & Forecast for Metabolic Disorders (US$ billion), By Country (2013 – 2020) ..............................................................52 Table 43. Global Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By Respiratory Disorders (2013 – 2020)........................................................................................................................52 Table 44. Global Prescription Pharmaceuticals Market Size & Forecast for Respiratory Disorders (US$ billion), By Regions (2013 – 2020) ................................................................................................53 Table 45. North America Prescription Pharmaceuticals Market Size & Forecast for Respiratory Disorders (US$ billion), By Country (2013 – 2020) ...............................................................................54 Table 46. Europe Prescription Pharmaceuticals Market Size & Forecast for Respiratory Disorders (US$ billion), By Country (2013 – 2020)................................................................................................54 Table 47. Asia Prescription Pharmaceuticals Market Size & Forecast for Respiratory Disorders (US$ billion), By Country (2013 – 2020) ........................................................................................................55

E

Table 48. Rest of the World (RoW) Prescription Pharmaceuticals Market Size & Forecast for Respiratory Disorders (US$ billion), By Country (2013 – 2020)............................................................55

PL

Table 49. Global Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By Other Therapeutic Segments (2013 – 2020) ...................................................................................................56

M

Table 50. Global Prescription Pharmaceuticals Market Size & Forecast for Other Therapeutic Segments (US$ billion), By Regions (2013 – 2020) ...............................................................................57

SA

Table 51. North America Prescription Pharmaceuticals Market Size & Forecast for Other Therapeutic Segments (US$ billion), By Country (2013 – 2020)...........................................................57 Table 52. Europe Prescription Pharmaceuticals Market Size & Forecast for Other Therapeutic Segments (US$ billion), By Country (2013 – 2020) ...............................................................................57 Table 53. Asia Prescription Pharmaceuticals Market Size & Forecast for Other Therapeutic Segments (US$ billion), By Country (2013 – 2020) ...............................................................................58 Table 54. Rest of the World (RoW) Prescription Pharmaceuticals Market Size & Forecast for Other Therapeutic Segments (US$ billion), By Country (2013 – 2020)...........................................................58 Table 55. Global Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By Formulations (2013 – 2020)..................................................................................................................59 Table 56.

Global Capsules Market Size & Forecast (US$ billion) (2013 – 2020)...............................60

Table 57.

Global Capsules Market Size & Forecast (US$ billion), By Regions (2013 – 2020) ...........61

Table 58.

Global Tablets Market Size & Forecast (US$ billion), (2013 – 2020) ................................62

Table 59.

Global Tablets Market Size & Forecast (US$ billion), By Regions (2013 – 2020)..............63

Table 60.

Global Inhalants and Liquids Market Size & Forecast (US$ billion), (2013 – 2020)..........64

Table 61.

2020)

Global Inhalants and Liquids Market Size & Forecast (US$ billion), By Regions (2013 – 65 12

Table 62.

Global Parenteral Market Size & Forecast (US$ billion), (2013 – 2020) ...........................65

Table 63.

Global Parenterals Market Size & Forecast (US$ billion), By Regions (2013 – 2020) ......66

Table 64.

Global Topicals Market Size & Forecast (US$ billion), (2013 – 2020) ...............................67

Table 65.

Global Topicals Market Size & Forecast (US$ billion), By Regions (2013 – 2020) ............68

Table 66. Global Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By Regions (2013 – 2020) ........................................................................................................................................69 Table 67. North America Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By Country (2013 – 2020) ..........................................................................................................................70 Table 68.

– 2020)

North America Prescription Pharmaceuticals Market Size & Forecast (US$ billion), (2013 70

Table 69. North America Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By Therapeutic Segments (2013 – 2020) ...................................................................................................71

E

Table 70. North America Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By Formulations (2013 – 2020)..................................................................................................................72

Table 72.

PL

Table 71. Europe Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By Country (2013 – 2020) ........................................................................................................................................73 Europe Prescription Pharmaceuticals Market Size & Forecast (US$ billion), (2013 – 2020) 73

M

Table 73. Europe Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By Therapeutic Segments (2013 – 2020) ...................................................................................................74

SA

Table 74. Europe Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By Formulations (2013 – 2020)..................................................................................................................74 Table 75.

– 2020)

Asia Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By Country (2013 75

Table 76.

Asia Prescription Pharmaceuticals Market Size & Forecast (US$ billion), (2013 – 2020).75

Table 77. Asia Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By Therapeutic Segments (2013 – 2020) .......................................................................................................................76 Table 78. Asia Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By Formulations (2013 – 2020) ........................................................................................................................................76 Table 79. RoW Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By Country, (2013 – 2020) ........................................................................................................................................77 Table 80.

RoW Prescription Pharmaceuticals Market Size & Forecast (US$ billion), (2013 – 2020) 77

Table 81. RoW Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By Therapeutic Segments (2013 – 2020) .......................................................................................................................78 Table 82. RoW Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By Formulations (2013 – 2020) ........................................................................................................................................78 13

Financial Overview: AstraZeneca plc (U.K.) (Europe) (2013 to 2015)...............................81

Table 84.

2015)

Revenues of Top-3 Pharmaceutical Products AstraZeneca plc (U.K.) (Europe) (2013 to ...........................................................................................................................................82

Table 85.

Financial Overview: Bayer AG (Germany) (Europe) (2013 to 2015) .................................83

Table 86.

2015)

Revenues of Top-3 Pharmaceutical Products: Bayer AG (Germany) (Europe) (2013 to ...........................................................................................................................................83

Table 87.

Financial Overview: Gilead Sciences, Inc. (U.S.) (2013 to 2015) .......................................84

Table 88.

Revenues of Top-3 Pharmaceutical Products: Gilead Sciences, Inc. (U.S.) (2013 to 2015) .. ...........................................................................................................................................85

Table 89.

Financial Overview: GlaxoSmithKline plc (U.K.) (Europe) (2013 to 2015) ........................85

Table 90. to 2015)

Revenues of Top-3 Pharmaceutical Products: GlaxoSmithKline plc (U.K.) (Europe) (2013 ...........................................................................................................................................86

Table 91.

Financial Overview: Johnson & Johnson (U.S.) (2013 to 2015) ........................................87

Table 92.

Revenues of Top-3 Pharmaceutical Products: Johnson & Johnson (U.S.) (2013 to 2015) 88

Table 93.

Financial Overview: Merck & Co., Inc. (U.S.) (2013 to 2015)............................................88

Table 94.

Revenues of Top-3 Pharmaceutical Products: Merck & Co., Inc. (U.S.) (2013 to 2015) ...89

Table 95.

Financial Overview: Novartis AG (Switzerland) (Europe) (2013 to 2015).........................90

Table 96. to 2015)

Revenues of Top-3 Pharmaceutical Products: Novartis AG (Switzerland) (Europe) (2013 ...........................................................................................................................................91

Table 97.

Financial Overview: Pfizer Inc. (U.S.) (2013 to 2015)........................................................91

Table 98.

Revenues of Top-3 Pharmaceutical Products: Pfizer Inc. (U.S.) (2013 to 2015) ...............92

Table 99.

Financial Overview: F. Hoffmann-La Roche (Switzerland) (Europe) (2013 to 2015) ........93

SA

M

PL

E

Table 83.

Table 100.

Revenues of Top-3 Pharmaceutical Products: Hoffmann-La Roche (Switzerland) (Europe) (2013 to 2015)........................................................................................................................94 Table 101.

Financial Overview: Sanofi S.A. (France) (Europe) (2013 to 2015) ...............................94

Table 102.

2015)

Revenues of Top-3 Pharmaceutical Products: Sanofi S.A. (France) (Europe) (2013 to .......................................................................................................................................95

Table 103.

Acronyms ......................................................................................................................96

14

List of Figures Figure 1.

Research Methodology .....................................................................................................16

Figure 2.

Prescription Pharmaceuticals Market Segmentation .......................................................17

Figure 3. Global Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By Therapeutic Segments (2015) ...................................................................................................................................34 Figure 4. Global Prescription Pharmaceuticals for Cardiovascular Disorders Market Size & Forecast (US$ billion), By Regions (2015 vs. 2020)..............................................................................................36 Figure 5. Global Prescription Pharmaceuticals for Oncology Market Size & Forecast (US$ billion),

By Regions (2015 vs. 2020) ...................................................................................................................40 Figure 6. Global Prescription Pharmaceuticals Market Size & Forecast for Inflammatory Conditions (US$ billion), By Regions (2015 vs. 2020)..............................................................................................43 Figure 7. Global Prescription Pharmaceuticals Market Size & Forecast for Metabolic Disorders (US$ billion), By Regions (2015 vs. 2020)..............................................................................................50

E

Figure 8. Global Prescription Pharmaceuticals Market Size & Forecast for Respiratory Disorders (US$ billion), By Regions (2015 vs. 2020)..............................................................................................53

PL

Figure 9. Global Prescription Pharmaceuticals Market Size & Forecast for Other Therapeutic Segments (US$ billion), By Regions (2015 vs. 2020).............................................................................56

M

Figure 10.

Global Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By Formulations (2015)..............................................................................................................................59 Global Capsules Market Size & Forecast (US$ billion), By Regions (2015 vs. 2020) ....61

Figure 12.

Global Tablets Market Size & Forecast (US$ billion), By Regions (2015 vs. 2020).......62

Figure 13. vs. 2020)

Global Inhalants and Liquids Market Size & Forecast (US$ billion), By Regions (2015 .......................................................................................................................................64

Figure 14.

Global Parenteral Market Size & Forecast (US$ billion), By Regions (2015 vs. 2020) .66

Figure 15.

Global Topicals Market Size & Forecast (US$ billion), By Regions (2015 vs. 2020) ......67

Figure 16.

Global Prescription Pharmaceuticals Market Size vs. CAGR% (2015 – 2020), By Regions .......................................................................................................................................69

Figure 17.

Market Share Analysis...................................................................................................80

Figure 18.

Market Positioning of Key Players ................................................................................80

SA

Figure 11.

15

Market Overview 1.1 Definitions The 'Global Prescription Pharmaceuticals Market – Market Size and Forecast (2013– 2020)' report includes market size and forecast estimates for the period 2013 to 2020. The scope of this report is cardiovascular disorders, inflammatory conditions, metabolic disorders, oncology, respiratory disorders, and other therapeutic segments. The report segments the market by therapeutic segments, formulations, and regions. The report includes market size and forecast estimates for all market segments in the study period. The report has 2015 as the base year, 2013 and 2014 as the historic years, and 2020 as the forecast year.

The therapeutic segments that are included in this report are cardiovascular

E

disorders, infectious diseases, inflammatory conditions, metabolic disorders, oncology, respiratory disorders, and other therapeutic segments. The formulation

PL

segments that are included in this report are capsules, inhalants, parenteral, tablets, and topicals. The regional market segments included in the report are Asia, Europe, North America, and Rest of the World.

M

1.2 Research Methodology

The research methodology for market research reports at ScalarMR includes a

SA

combination of top-down and bottom-up research formats. Continuous market tracking, rigorous fact-checking, data-triangulation, and multiple layers of quality control ensure high-quality data that can be leveraged for actionable insights.

ScalarMR’s research methodology starts with extensive secondary, research.

Important secondary sources include SEC filings, annual reports, financial reports, investor presentations, and technical & industry publications. Secondary research helps build a comprehensive map of the structure of the market. It helps identify key players in all market segments and helps build their profiles by identifying their financials, product portfolios, and growth strategies. It also identifies qualitative market factors like regulatory scenario, patent estates, and market developments.

Figure 1. Research Methodology

16

Top-down

Global

Global Market Size

Market Size Market-specific Revenues of Key Market Players

Segment-specific Market Size

Regional Revenues of Key Market Players

Market Size

Bottom-up

A bottom-up market sizing format is used to arrive at the top-line market size.

Revenues of key market players used to arrive at the market-specific revenues of

E

each key market player. A process of inward bracketing is used to arrive at the market-specific revenues for each key market player. The market specific revenues

PL

are combined to arrive at the top-line global market size. Segment-specific and regional market sizes are estimated through top-down market sizing.

M

Data synthesis and triangulation techniques are used to develop the market model.

The model represents current consensus market opinion. The market estimates from

SA

the model are used to generate reports that include qualitative and quantitative insights into the market.

1.3 Market Segmentation

Figure 2. Prescription Pharmaceuticals Market Segmentation Prescription Pharmaceuticals Market, by Therapeutic Segments Cardiovascular Disorders

Infectious Diseases

Inflammatory Conditions

Metabolic Disorders

17

Oncology

Respiratory Disorders

Other Therapeutic Segments

Prescription Pharmaceuticals Market, by Formulations

Capsules

Inhalants

Parenterals

Tablets

Topicals

Prescription Pharmaceuticals Market, by Regions

Europe

North America

Rest of the World

SA

M

PL

E

Asia

18

1 Executive Summary The global prescription pharmaceutical market was estimated to be US$ 726.89 billion in 2015. This market is expected to grow at a CAGR of 4.80% in the forecast period and is expected to be US$ 918.74 billion in 2020. This report segments the prescription pharmaceuticals market by therapeutic segments, formulations and regions.

1.1 Global Prescription Pharmaceuticals Market Table 1.

Global Prescription Pharmaceuticals Market

Global Prescription Pharmaceuticals Market

2015

2020

CAGR% (2015 – 2020)

726.89

918.74

4.80

E

Total

Market Size (US$ billion)

Cardiovascular Disorders

Metabolic Disorders Respiratory Disorders Other Therapeutic Segments

Tablets

M

Infectious Diseases

Capsules

Formulations

PL

Inflammatory Conditions

SA

Therapeutic Segments

Oncology

Inhalants and Liquids Parenterals Topicals North America

Regions

Europe Asia RoW

Source: Scalar Market Research Analysis

19

1.2 Global Prescription Pharmaceuticals Market Size (US$ Billion), By Therapeutic Segments (2015 vs. 2020) Table 2.

Global Prescription Pharmaceuticals Market Size (US$ Billion), By Therapeutic Segments (2015 vs. 2020)

Table 3.

Cardiovascular Disorders

5.21 4.58

Oncology

Inflammatory Conditions 2015

Infectious Diseases 2020

Metabolic Disorders

Respiratory Disorders

193.03

154.34

44.06

36.87

107.55

83.44

125.62

95.38

138.36

110.28

152.20

3.63

117.53

157.91

4.12

129.05

Market Size (USD Billion)

4.64

CAGR% (2015 – 2020)

5.66

5.31

Other Therapeutic Segments

CAGR% (2015 – 2020)

E

Source: Scalar Market Research Analysis

The therapeutic segments of the prescription pharmaceuticals market included in this

PL

report are cardiovascular disorders, oncology, inflammatory conditions, infectious diseases, metabolic disorders, respiratory disorders, and other therapeutic segments. Cardiovascular disorders were the largest therapeutic segment in 2015.

M

This segment was estimated to be US$ XX billion in 2015. On the other hand, infectious diseases are expected to be the fastest-growing therapeutic segment in

SA

the forecast period. This market segment is expected to grow at a CAGR of XX% between 2015 and 2020.

20

1.3 Global Prescription Pharmaceuticals Market Size (US$ Billion), By Formulations (2015 vs. 2020) Global Prescription Pharmaceuticals Market Size (US$ Billion), By Formulations (2015 vs. 2020)

4.23

4.70

4.19

Capsules

Parenterals

41.06

34.99

Topicals

CAGR% (2015 – 2020)

E

2020

89.76

71.34

Inhalants and Liquids

Tablets 2015

127.34

103.69

304.42

247.42

356.16

3.26

CAGR% (2015 – 2020)

5.74

269.45

Market Size (USD Billion)

Table 4.

Source: Scalar Market Research Analysis

PL

The formulation segments of the prescription pharmaceuticals market included in this report are capsules, tablets, inhalants and liquids, parenteral, and topicals. Capsules were the largest formulation segment in 2015. This segment was estimated to be

M

US$ XX billion in 2015. It is also expected to be the fastest-growing formulation segment in the forecast period. This market segment is expected to grow at a CAGR

SA

of XX% between 2015 and 2020.

1.4 Global Prescription Pharmaceuticals Market Size (US$ Billion), By Regions (2015 vs. 2020) Global Prescription Pharmaceuticals Market Size (US$ Billion), By Regions (2015 vs. 2020)

5.32

North America

Europe 2015

2020

Asia CAGR% (2015 – 2020) 21

115.40

89.04

219.73

158.10

219.20

3.57

183.98

364.41

295.77

4.26

RoW

CAGR% (2015 – 2020)

6.80

Market Size (USD Billion)

Table 5.

Source: Scalar Market Research Analysis

The regional segments of the prescription pharmaceuticals market included in this report are North America, Europe, Asia, and Rest of the World (RoW). North America was the largest regional segment in 2015. This segment was estimated to be US$ XX billion in 2015. On the other hand, Asia is expected to be the fastestgrowing regional segment in the forecast period. This market segment is expected to

SA

M

PL

E

grow at a CAGR of XX% between 2015 and 2020.

22

2 Market Overview 2.1 Drivers 2.1.1 Increase in the Ageing Population and Lengthening Life Expectancies According to the World Health Organization (WHO), in 2010 around 8% of the global population was aged 65 years and above. In 2015, the elderly population comprised around 12% of the global population. It has been estimated that by 2050, about 2.1 billion people will be aged above 60 years. The evolution of the population structure will lead to increased pressure on long-term publicly-funded health, support programmes for older people. There will be a paradigm shift from acute to chronic illnesses thereby leading to an increased use of prescription pharmaceuticals.

The rising life expectancy within the older population segment is leading to an

E

increase in the number and proportion of people at very old ages. People aged 85 or older constitute around 12% and 6% of world’s 65 and above population in

PL

developed and developing economies respectively. According to Economist Intelligence Unit (EIU), life expectancy is expected to increase from an estimated 72.7 years in 2013 to 73.7 years by 2018. This will result in a rise in global health

M

care and life sciences spending.

SA

2.1.2 Rising Affluence in Emerging Markets Growing consumer wealth and income levels, increasing government and patient awareness, and a trend towards healthier lifestyles are anticipated to boost health care spending to around 8.1% between 2014 and-2018 in Asia. Factors such as government focus on broader welfare policies and economic expansion will drive the market for prescription pharmaceuticals. BRICS (Brazil, Russia, India, China, and South Africa) are among the fastest-growing global economies. According to the World Economic Forum report, by 2022 around one-third of all global health expenditure will occur in emerging economies. Increased healthcare spending and improved access to healthcare in emerging economies will drive the global prescription pharmaceuticals market.

2.1.3 Widespread Prevalence of Chronic Diseases Chronic diseases namely, heart disease, stroke, cancer, type 2 diabetes, obesity, and arthritis pose a serious threat to the health of world population. The mortality 23

formation of the ASEAN Economic Community (AEC) to define the regulatory landscape for this region.

Thus, across the globe, a strong trend is being observed towards consolidation of legislature systems into a global drug safety system with balanced business processes.

3.3 Macroeconomic Indicators 3.3.1 Healthcare Spending (US$ Billion), by Regions (2005 to 2014) Table 6.

Healthcare Spending (US$ Billion), by Regions (2005 to 2014)

Regions

2005

2006

2007

2008

2009

2011

2012

2013

2014

CAGR% (2005– 2014)

E

Asia

2010

PL

Europe North America Rest of the World

M

Total

Source: World Bank and Scalar Market Research Analysis

Table 7.

SA

3.3.2 Per Capita Healthcare Spending (US$), by Regions (2005 to 2014) Per Capita Healthcare Spending (US$), by Regions (2005 to 2014)

Regions

2005

2006

2007

2008

2009

2010

2011

2012

2013

2014

CAGR% (2005– 2014)

Asia Europe North America Rest of the World

Total Source: World Bank and Scalar Market Research Analysis

3.3.3 Public Healthcare Spending (US$ Billion), by Regions (2005 to 2014) Table 8.

Public Healthcare Spending (US$ Billion), by Regions (2005 to 2014)

30

Regions

2005

2006

2007

2008

2009

2010

2011

2012

2013

2014

CAGR% (2005– 2014)

Asia Europe North America Rest of the World

Total Source: World Bank and Scalar Market Research Analysis

3.4 Ecosystem Analysis 3.4.1 Market Size of Top-25 Prescription Pharmaceuticals (2013 to 2015) Market Size of Top-25 Prescription Pharmaceuticals (2013 to 2015)

Product

Company

Indication

1

Humira

AbbVie Inc. (U.S.)

Rheumatoid arthritis and other inflammatory conditions

2

Harvoni

Gilead Sciences, Inc. (U.S.)

Hepatitis C

3

Enbrel

Amgen Inc. (U.S.), Pfizer Inc. (U.S.), Takeda Pharmaceutical Company Ltd. (Japan)

4

Remicade

5

2015 (US$ million)

2014 (US$ million)

2013 (US$ million)

Annual Growth (2014 to 2015)

Annual Growth (2013 to 2014)

U.S. Patent Expiry

14,021

12,543

10,659

11.78%

17.68%

December 2016

13,864

2,127

N.A.

551.81 %

N.A.

2030

Rheumatoid arthritis, psoriasis, and other inflammatory conditions

9,027

8,917

8,742

1.23%

2.00%

August 2019

Johnson & Johnson (U.S.), Merck & Co. (U.S.), Mitsubishi Tanabe Pharma Corporation (Japan)

Anti-TNF alpha drug for inflammatory disorders

8,957

9,889

9,646

-9.42%

2.52%

September 2018

Lantus

Sanofi S.A. (France)

Diabetes

7,209

7,157

6,448

0.73%

11.00%

August 2014

6

Avastin

F. Hoffmann-La Roche AG (Switzerland)

Cancer

6,905

6,629

6,461

4.16%

2.60%

2019

7

Herceptin

F. Hoffmann-La Roche AG (Switzerland)

Cancer

6,754

6,483

6,280

4.18%

3.23%

2019

8

Prevnar Family

Pfizer Inc. (U.S.)

Pneumococcal vaccine

6,245

4,464

3,974

39.90%

12.33%

2026

9

MabThera

F. Hoffmann-La Roche

Cancer

5,827

5,788

5,950

0.67%

-2.72%

2015

SA

M

PL

No.

E

Table 9.

31

4 Prescription Segments

Pharmaceuticals

Markets,

by

Therapeutic

4.1 Introduction The therapeutic segments of the prescription pharmaceuticals market included in this report are cardiovascular disorders, oncology, inflammatory conditions, infectious diseases, metabolic disorders, respiratory disorders, and other therapeutic segments. Cardiovascular disorders were the largest therapeutic segment in 2015, while infectious diseases are expected to be the fastest-growing therapeutic segment in the forecast period.

4.1.1 Global Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By Therapeutic Segments (2015)

E

Figure 3. Global Prescription Pharmaceuticals Market Size & Forecast (US$ billion),

By Therapeutic Segments (2015)

PL

Cardiovascular Disorders | USD 129.05 Billion Oncology | USD 117.53 Billion Inflammatory Conditions | USD 110.28 Billion

M

Infectious Diseases | USD 95.38 Billion Metabolic Disorders | USD 83.44 Billion

SA

Respiratory Disorders | USD 36.87 Billion

Other Therapeutic Segments | USD 154.34 Billion

Total | USD 726.89 Billion

Source: Scalar Market Research Analysis

Cardiovascular disorders, oncology, and inflammatory conditions were the three largest therapeutic segments of the prescription pharmaceuticals market in 2015.

The combined share of these three therapeutic segments was XX% in 2015.

4.1.2 Global Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By Therapeutic Segments (2013 – 2020) Table 11.

Global Prescription Pharmaceuticals Market Size & Forecast (US$ billion),

By Therapeutic Segments (2013 – 2020)

Therapeutic Segments

2013

2014

2015

2016

Cardiovascular Disorders 34

2017

2018

2019

2020

CAGR% (2015 – 2020)

Oncology Inflammatory Conditions Infectious Diseases Metabolic Disorders Respiratory Disorders Other Therapeutic Segments Total Source: Scalar Market Research Analysis

Cardiovascular disorders were the largest therapeutic segment of the prescription pharmaceuticals market in 2015. This market segment is expected to grow at a CAGR of XX% from US$ XX billion in 2015 to US$ XX billion in 2020.

According to 2015 American Heart Association statistics, cardiovascular disorders

E

account for 17.3 million deaths per year and is expected to grow to over 23.6 million

PL

deaths by 2030. In the year 2011, around 787,000 people in the U.S. died from stroke, heart disease and other cardiovascular diseases in 2011. The cardiovascular disorders tend to account for more deaths in comparison to all forms of cancer

M

combined.

4.2 Cardiovascular Disorders

SA

Cardiovascular disorder was the largest therapeutic segments in 2015. This segment includes a wide range of disease categories including hypertension, dyslipidemia, stroke, atherosclerosis, thrombosis, and coronary artery disease. According to World Heart Federation, the risk factors for cardiovascular disorders include unchangeable factors such as age, sex, and heredity, and changeable factors like diet, obesity, tobacco consumption, stress, and physical inactivity. The rate of cardiovascular disorders is high in developed and rapidly increasing in developing countries dues to changes in lifestyle and nutrition.

35

4.2.1 Global Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By Cardiovascular Disorders, (2013 – 2020) Table 12.

Global Prescription Pharmaceuticals Market Size & Forecast (US$ billion),

By Cardiovascular Disorders, (2013 – 2020) 2013

2014

2015

2016

2017

2018

2019

2020

CAGR% (2015 – 2020)

Market Size (US$ Billion) Annual Growth Rate (%) Source: Scalar Market Research Analysis

The global prescription pharmaceuticals for cardiovascular disorders market grew from US$ XX billion in 2013 to US$ XX billion in 2015. This market is expected to grow at an annual growth rate of between XX% and XX% in the forecast period. It is

E

expected to have a CAGR of XX% between 2015 and 2020.

PL

4.2.2 Global Prescription Pharmaceuticals for Cardiovascular Disorders Market Size & Forecast (US$ billion), By Regions (2015 vs. 2020)

M

4.69

North America

Europe 2015

2020

Asia

19.21

15.27

36.36

26.98

38.02

32.93

64.31

2.92

CAGR% (2015 – 2020)

SA

6.15

3.61

53.86

Market Size (USD Billion)

Figure 4. Global Prescription Pharmaceuticals for Cardiovascular Disorders Market Size & Forecast (US$ billion), By Regions (2015 vs. 2020)

RoW

CAGR% (2015 – 2020)

Source: Scalar Market Research Analysis

Asia is expected to be the fastest-growing regional segment of the prescription pharmaceuticals for cardiovascular disorders market in the forecast period. This market segment is estimated to grow at a CAGR of XX% from US$ XX billion in 2015 to US$ XX billion in 2020.

The prevalence of cardiovascular risk factors like high cholesterol, hypertension, obesity, and diabetes have been on a rise in the rise in Asia, particularly Japan.

36

According to the American Heart Association, in Asia, around 21.0% have hypertension, 3.7% have CHD, 6.1% have heart disease, and 1.9% has had a stroke. According to WHO, over 80% of all deaths occur due to cardiovascular disorders in developing countries.

4.2.3 Global Prescription Pharmaceuticals for Cardiovascular Disorders Market Size & Forecast (US$ billion), By Regions (2013 – 2020) Table 13.

Global Prescription Pharmaceuticals for Cardiovascular Disorders Market Size & Forecast (US$ billion), By Regions (2013 – 2020)

Regions

2013

2014

2015

2016

2017

2018

2019

2020

CAGR% (2015 – 2020)

North America Europe

E

Asia

PL

RoW Total Source: Scalar Market Research Analysis

M

North America was the largest regional segment of the prescription pharmaceuticals for cardiovascular disorders market in 2015. This market segment is estimated to

SA

grow at a CAGR of XX% from US$ XX billion in 2015 to US$ XX billion in 2020.

Apart from a high prevalence of cardiac diseases, the soaring prices for prescription drugs in North America also accounts for the large market size of prescription pharmaceuticals.

4.2.4 North America Prescription Pharmaceuticals for Cardiovascular Disorders Market Size & Forecast (US$ billion), By Country (2013 – 2020) Table 14.

Country

North America Prescription Pharmaceuticals for Cardiovascular Disorders Market Size & Forecast (US$ billion), By Country (2013 – 2020) 2013

2014

2015

2016

U.S. Canada Total Source: Scalar Market Research Analysis

37

2017

2018

2019

2020

CAGR% (2015 – 2020)

4.2.5 Europe Prescription Pharmaceuticals for Cardiovascular Disorders Market Size & Forecast (US$ billion), By Country (2013 – 2020) Table 15.

Europe Prescription Pharmaceuticals for Cardiovascular Disorders Market Size & Forecast (US$ billion), By Country (2013 – 2020)

Country

2013

2014

2015

2016

2017

2018

2019

2020

CAGR% (2015 – 2020)

France Germany U.K. Rest of Europe Total Source: Scalar Market Research Analysis

Asia Prescription Pharmaceuticals for Cardiovascular Disorders Market Size (US$ Billion) for Asia, By Country (2013 – 2020) 2013

2014

India Rest of Asia Total

2016

2017

2018

2019

2020

CAGR% (2015 – 2020)

SA

China Japan

2015

M

Country

PL

Table 16.

E

4.2.6 Asia Prescription Pharmaceuticals for Cardiovascular Disorders Market Size (US$ Billion) & Forecast (US$ billion), By Country (2013 – 2020)

Source: Scalar Market Research Analysis

4.2.7 Rest of the World (RoW) Prescription Pharmaceuticals for Cardiovascular Disorders Market Size & Forecast (US$ billion), By Country (2013 – 2020) Table 17.

Rest of the World (RoW) Prescription Pharmaceuticals for Cardiovascular Disorders Market Size & Forecast (US$ billion), By Country (2013 – 2020)

Country

2013

2014

2015

2016

Latin America Middle East and Africa 38

2017

2018

2019

2020

CAGR% (2015 – 2020)

Total Source: Scalar Market Research Analysis

4.3 Oncology According to National Cancer Institute (U.S.), about 1.6 million new cases of cancer will be diagnosed, and about 0.6 million people will die from the disease in the year 2016. According to a study carried out by the National Cancer Institute (U.S.) between 2008 and 2012, the incidence of cancer cases was 454.8 per 100,000 people per year. Furthermore, the number of deaths due to cancer death was 171.2 per 100,000 individuals per year. Cancer mortality was observed to be higher among men than women (207.9 per 100,000 men and 145.4 per 100,000 for women).

Approximately 39.6 % of men & women will be diagnosed with cancer at some point during their lifetimes. The national expenditure on cancer in the U.S. was US$ 125

E

billion in 2010 and could reach US$ 156 billion by 2020.

Global Prescription Pharmaceuticals Market Size & Forecast (US$ billion),

By Oncology (2013 – 2020) 2013

2014

2016

2017

2018

2019

2020

CAGR% (2015 – 2020)

SA

Market Size (US$ Billion)

2015

M

Table 18.

PL

4.3.1 Global Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By Oncology (2013 – 2020)

Annual Growth Rate (%)

Source: Scalar Market Research Analysis

The global prescription pharmaceuticals for oncology market grew from US$ XX billion in 2013 to US$ XX billion in 2015. This market is expected to grow at an annual growth rate of between XX% and XX% in the forecast period. It is expected to have a CAGR of XX% between 2015 and 2020.

39

5 Prescription Pharmaceuticals Markets, by Formulations 5.1 Introduction The formulation segments of the prescription pharmaceuticals market included in this report are capsules, tablets, inhalants and liquids, parenteral, and topicals.

Capsules were the largest formulation segment in 2015, and it is also expected to be the fastest-growing formulation segment in the forecast period. The rise in the geriatric population, the upsurge in the consumer preferences for capsules and proliferation of pharmaceutical industries globally are factors responsible for the growth of this formulation segment.

5.1.1 Global Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By Formulations (2015)

PL

E

Figure 10. Global Prescription Pharmaceuticals Market Size & Forecast (US$ billion),

By Formulations (2015)

Capsules | USD 269.45 Billion

M

Tablets | USD 247.42 Billion

Inhalants and Liquids | USD 103.69 Billion

SA

USD 726.89 Billion

Parenterals | USD 71.34 Billion Topicals | USD 34.99 Billion

Source: Scalar Market Research Analysis

Capsules, tablets, and inhalants and liquids were the three largest formulation segments of the prescription pharmaceuticals market in 2015. The combined share of these three formulation segments was XX% in 2015.

5.1.2 Global Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By Formulations (2013 – 2020) Table 55.

Formulations

Global Prescription Pharmaceuticals Market Size & Forecast (US$ billion),

By Formulations (2013 – 2020) 2013

2014

2015

2016

Capsules 59

2017

2018

2019

2020

CAGR% (2015 – 2020)

Tablets Inhalants and Liquids Parenterals Topicals Total Source: Scalar Market Research Analysis

Capsules were the largest formulation segment of the prescription pharmaceuticals market in 2015. This market segment is expected to grow at a CAGR of XX% from US$ XX billion in 2015 to US$ XX billion in 2020.

Technological advancements are resulting in capsule dosing for dry powder inhalers, vegetarian capsules or non-gelatin capsules, solid lipid pellet capsules and capsule-

E

in-capsule for sustained release effect, is expected to result in the growth of this market.

PL

5.2 Capsules

Capsules are solid dosage form and the drugs that are enclosed in a hard or soft soluble container. The container is usually of a derivative of gelatine. This dosage

M

form is used by manufacturers when the drug cannot be compacted into a solid tablet. Drugs administered in capsules forms are used for the treatment of

SA

gastrointestinal diseases, neurological diseases, oncology, infectious diseases, cardiovascular diseases, haematological diseases, and inflammatory diseases.

5.2.1 Global Capsules Market Size & Forecast (US$ billion) (2013 – 2020) Table 56.

Global Capsules Market Size & Forecast (US$ billion) (2013 – 2020) 2013

2014

2015

2016

2017

2018

2019

2020

CAGR% (2015 – 2020)

Market Size (US$ Billion) Annual Growth Rate (%) Source: Scalar Market Research Analysis

The global capsules market grew from US$ XX billion in 2013 to US$ XX billion in 2015. This market is expected to grow at an annual growth rate of between XX% and XX% in the forecast period. It is expected to have a CAGR of XX% between 2015 and 2020.

60

5.2.2 Global Capsules Market Size & Forecast (US$ billion), By Regions (2015 vs. 2020) Figure 11. Global Capsules Market Size & Forecast (US$ billion), By Regions (2015 vs. 2020)

2015

Asia

2020

47.57

35.24

RoW

CAGR% (2015 – 2020)

PL

Source: Scalar Market Research Analysis

90.28

62.34

Europe

E

North America

84.61

68.05

133.71

4.45

CAGR% (2015 – 2020)

6.18 5.19

103.82

Market Size (USD Billion)

7.69

Asia is expected to be the fastest-growing regional segment of the capsules market in the forecast period. This market segment is expected to grow at a CAGR of XX%

M

from US$ XX billion in 2015 to US$ XX billion in 2020. Owing to rise in health awareness, affordability of healthcare services, and the growing number of

SA

pharmaceutical industries, the Asia capsules market is expected to grow at a high CAGR during the forecast period.

5.2.3 Global Capsules Market Size & Forecast (US$ billion), By Regions (2013 – 2020) Table 57.

Regions

Global Capsules Market Size & Forecast (US$ billion), By Regions (2013 – 2020) 2013

2014

2015

2016

North America Europe Asia RoW Total Source: Scalar Market Research Analysis 61

2017

2018

2019

2020

CAGR% (2015 – 2020)

6 Geographic Analysis 6.1 Introduction The regional segments of the prescription pharmaceuticals market included in this report are North America, Europe, Asia, and Rest of the World (RoW). North America was the largest regional segment in 2015, while Asia is expected to be the fastest-growing regional segment in the forecast period.

6.1.1 Global Prescription Pharmaceuticals Market Size vs. CAGR% (2015 – 2020), By Regions Figure 16. Global Prescription Pharmaceuticals Market Size vs. CAGR% (2015 – 2020),

By Regions

Asia (2020)

RoW (2020)

RoW (2015)

5 Europe (2015)

4 3

0

North America (2015)

PL

6

E

Asia (2015)

7

50

100

North America (2020)

Europe (2020)

M

CAGR% (2015 – 2020)

8

150

200

250

300

350

400

SA

Market Size (USD Billion)

Source: Scalar Market Research Analysis

North

America

was

the

largest

regional

segments

of

the

prescription

pharmaceuticals market in 2015. The market had a XX% share of the global market in 2015.

6.1.2 Global Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By Regions (2013 – 2020) Table 66.

Regions

Global Prescription Pharmaceuticals Market Size & Forecast (US$ billion),

By Regions (2013 – 2020) 2013

2014

2015

2016

North America Europe

69

2017

2018

2019

2020

CAGR% (2015 – 2020)

Asia RoW Total Source: Scalar Market Research Analysis

North America was the largest regional segment of the prescription pharmaceuticals market in 2015. This market segment is expected to increase at a CAGR of XX% from US$ XX billion in 2015 to US$ XX billion in 2020.

6.2 North America North America accounted for the largest share of the global prescription pharmaceuticals market with US$ XX billion in 2015. Factors such as technological advancements, rising incidences of chronic diseases, and positive government initiatives are considered as the major driving factor for the growth of prescription

E

pharmaceuticals market in North America.

North America Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By Country (2013 – 2020)

U.S. Canada Total

2013

2014

2015

2016

2017

2018

2019

2020

CAGR% (2015 – 2020)

SA

Country

M

Table 67.

PL

6.2.1 North America Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By Country (2013 – 2020)

Source: Scalar Market Research Analysis

6.2.2 North America Prescription Pharmaceuticals Market Size & Forecast (US$ billion), (2013 – 2020) Table 68.

North America Prescription Pharmaceuticals Market Size & Forecast (US$ billion), (2013 – 2020) 2013

2014

2015

2016

Market Size (US$ Billion) Annual Growth Rate (%) Source: Scalar Market Research Analysis

70

2017

2018

2019

2020

CAGR% (2015 – 2020)

The prescription pharmaceuticals market in North America grew from US$ XX billion in 2013 to US$ XX billion in 2015. This market is expected to grow at an annual growth rate of between XX% and XX% in the forecast period. It is expected to have a CAGR of XX% between 2015 and 2020.

Increased healthcare spending, expanding consumer access to health care owing to the 2010 Patient Protection and Affordable Care Act (ACA), aging population, and widespread rise of chronic diseases are fuelling the growth of prescription pharmaceuticals in North America. The significant growth in biologics sales has also boosted the prescription pharmaceuticals market. Also, North America possesses a traditional stronghold of pharmaceutical innovation that is expected to augment this market further.

Therapeutic Segments

2013

Cardiovascular Disorders

2015

2016

2017

2018

2019

2020

CAGR% (2015 – 2020)

SA

Oncology

2014

PL

North America Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By Therapeutic Segments (2013 – 2020)

M

Table 69.

E

6.2.3 North America Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By Therapeutic Segments (2013 – 2020)

Inflammatory Conditions Infectious Diseases Metabolic Disorders Respiratory Disorders Other Therapeutic Segments Total

Source: Scalar Market Research Analysis

Cardiovascular disorders were the largest therapeutic segment of the prescription pharmaceuticals market in North America in 2015. This market segment is expected to grow at a CAGR of XX% from US$ XX billion in 2015 to US$ XX billion in 2020.

71

6.2.4 North America Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By Formulations (2013 – 2020) Table 70.

North America Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By Formulations (2013 – 2020)

Formulations

2013

2014

2015

2016

2017

2018

2019

2020

CAGR% (2015 – 2020)

Capsules Tablets Inhalants and Liquids Parenterals Topicals Total

E

Source: Scalar Market Research Analysis

Capsules were the largest formulation segment of the prescription pharmaceuticals

PL

market in North America in 2015. This market segment is expected to grow at a

SA

M

CAGR of XX% from US$ XX billion in 2015 to US$ 133.71 billion in 2020.

72

7 Competitive Landscape 7.1 Market Share Analysis The market share analysis studies the market share of the leading players operating in the prescription pharmaceuticals market. This market share analysis exclusively focused on prescription pharmaceuticals products and is estimated based on considering the global pharmaceutical products market revenue for the year 2015. The value percentage for each company is based on the analysis of company’s investor presentations, annual reports, press releases, product offering particular to prescription pharmaceuticals segment and opinion of primary respondents. The below market share diagram represents the revenue regarding value percentage for 2015 for each leading players operating in this market.

Figure 17. Market Share Analysis

Johnson & Johnson Roche

E

4.1% 5.2% 5.0%

PL

Pfizer

6.0%

Bayer AG

2.0% 4.8%

Merck & Co., Inc.

3.8%

GlaxoSmithKline Plc

M

58.2%

Novartis AG

SA

4.7% 3.2% 3.0%

Sanofi Gilead Sciences Astrazeneca Others

Source: Scalar Market Research Analysis

7.2 Market Positioning of Key Players The figure below represents the top-10 companies based on the criteria's: annual revenue, combined total revenue of top-3 drug products, annual growth, and R&D investment.

Figure 18. Market Positioning of Key Players

80

9 SCALAR 360 DEGREE MARKET REVIEW The usage of prescription drugs over the years is set to increase across the globe. Nearly half of this volume growth is expected to occur in emerging markets, with India, China, Brazil and Indonesia driving the spike in demand. In the developed markets, the volume of medicine use will remain stable. However, there will be an inclination towards the use of branded products as the use of biologics, or specialty medicines become more prevalent. The generic drugs, over the counter (OTC) products and imitative branded products, will fare better in the pharmerging markets and account for around 88% of total medicine use by 2020. The innovative specialty medicines have low adoption rates in these countries.

Over the forecast period, a large number of innovative medicines is set to emerge from R&D pipelines with products being focused on cancer, hepatitis C, autoimmune disorders, heart disease and some rare diseases. Owing to the presence of unparalleled treatment options, availability of cheap drugs and increased use of evidence for decision making, stakeholders across the globe are set to obtain a higher return for their medicine investment than before.

PL

E

The rapid development of technology will lead to changes in the treatment protocols, increase the patient accountability and engagement, and accelerate the rate of adoption of behavioral changes thereby improving patient adherence to treatments. Patients suffering from multiple chronic disorders can use wearables, mobile apps and other technologies to interact with providers and manage their health.

M

The healthcare spending levels in developed markets will increase owing to branded drugs whereas generics will drive the spending levels in pharmerging markets. However, owing to the patent expiries, around $150 billion would be saved on branded products, while over $30-40 billion would be saved on biologics as biosimilars become widely adopted. Also, a large number of drugs focused on chronic, rare or genetic diseases are expected to be launched thereby rendering significant clinical value.

SA

Thus, the market is undergoing an evolution with traditional bigwigs, such as U.S and Europe, flipping over, and emerging markets giving rise to new potential markets. The healthcare investors also require rethinking a strategy by keeping an eagle eye on the emerging markets. They need to make sure that they are not left behind owing to their low understanding of the true engines for growth.

10 Appendix 10.1 Acronyms Table 103. Acronyms OTC

Over the Counter

U.S.

United States

GIP

Global Innovative Pharma

GEP

Global Established Pharma

VOC

Vaccines, Oncology and Consumer Healthcare

R&D

Research and Development 96

United Kingdom

HCV

Hepatitis C virus

HIV

Human Immunodeficiency Virus

RoW

Rest of the World

CAGR

Compound annual growth rate

ACA

Patient Protection and Affordable Care Act

COPD

Chronic obstructive pulmonary disease

WHO

World Health Organization

AARDA

American Autoimmune Related Diseases Association

IMID

Immune-mediated inflammatory diseases

SLE

Systemic Lupus Erythematosus

RA

Rheumatoid Arthritis

E

U.K.

Chronic Heart Disease

PL

CHD ASEAN

Association of South-East Asian Nations

EMA IDMP

SA

GVP

ASEAN Economic Community

M

AEC

European Medicines Agency

Identification of Medicinal Products Good Pharmacovigilance Practices

FDA

Food and Drug Administration

GUDID

Global Unique Device Identification Database

97